Yervoy (Ipilimumab)
ipilimumab 200 mg/40 mL injection, 40 mL vial · INJECTION · PBS code 2638W
STREAMLINEDWhat it costs
AU$21378.52 PBS-determined price per pack
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2013-08-01.
- • Repeats: 1.
- • PBS program: IN.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Stage III melanoma
Patient must not have received prior PBS-subsidised treatment for this condition; AND
The treatment must be in addition to complete surgical resection; AND
Patient must have a WHO performance status of 1 or less; AND
The treatment must be in combination with PBS-subsidised treatment with nivolumab.
Prescribed amounts must be consistent with the treatment protocol used for an individual patient.
When ipilimumab is initially prescribed as a 3-weekly dosing regimen, patients must only receive a maximum of 80 mg every 3 weeks for 2 cycles (i.e., 1 repeat), in combination with nivolumab.
Sponsor: Bristol-Myers Squibb Australia Pty Ltd ABN 33 004 333 322
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.